Furthermore, they observed a higher percentage of CD3+ EVs with co-expression of immunoregulatory proteins PD-L1, CD15s, CTLA4, and COX-2 in patients with stage III or IV compared to stage I and II, confirming the usefulness of EVs as promising non-invasive cancer biomarkers and their immunomodulation potential [40]. Here, CD274 is linked to cancer.